Literature DB >> 11689168

Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain.

K Yasojima1, E G McGeer, P L McGeer.   

Abstract

beta-Amyloid peptide (Abeta) is generated by two cleavages of amyloid precursor protein (APP). The initial cleavage by BACE is followed by gamma-secretase cleavage of the C-terminal APP fragment. Presenilin-1 (PS-1) is intimately related to gamma-secretase. Once formed, Abeta is mainly broken down by neprilysin. To estimate vulnerability to Abeta senile plaque formation, we measured the relative mRNA levels of APP695, APP751, APP770, BACE, presenilin-1 (PS-1) and neprilysin in nine brain areas and in heart, liver, spleen and kidney in a series of Alzheimer disease (AD) and control cases. Each of the mRNAs was expressed in every tissue examined. APP695 was the dominant APP isoform in brain. Compared with controls, APP695 and PS-1 mRNA levels were significantly elevated in high plaque areas of AD brain, while neprilysin mRNA levels were significantly reduced. BACE levels were not significantly different in AD compared with control brain. In peripheral organs, there were no significant differences in any of the mRNAs between AD and control cases. APP isoforms were differently expressed in the periphery than in brain, with APP 751>770>695. Neprilysin mRNA levels were much higher, while APP695 and PS-1 mRNA levels were much lower in the periphery than in brain. The data suggest that, in the periphery, the capacity to degrade Abeta is srong, accounting for the failure of Abeta deposits to form. In plaque prone areas of AD brain, the capacity to degrade Abeta is weak, while the capacity to generate Ab is upregulated. In plaque resistant areas of brain, a closer balance exists, but there is some tendency towards lower degrading and higher synthesizing capacity in AD brain compared with control brain. Overall, the data indicate that effectiveness of degradation by neprilysin may be a key factor in determining whether Abeta deposits develop.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11689168     DOI: 10.1016/s0006-8993(01)03008-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  61 in total

1.  BACE2 expression increases in human neurodegenerative disease.

Authors:  Christopher J Holler; Robin L Webb; Ashley L Laux; Tina L Beckett; Dana M Niedowicz; Rachel R Ahmed; Yinxing Liu; Christopher R Simmons; Amy L S Dowling; Angela Spinelli; Moshe Khurgel; Steven Estus; Elizabeth Head; Louis B Hersh; M Paul Murphy
Journal:  Am J Pathol       Date:  2011-11-07       Impact factor: 4.307

Review 2.  Current therapeutic targets for the treatment of Alzheimer's disease.

Authors:  Joshua D Grill; Jeffrey L Cummings
Journal:  Expert Rev Neurother       Date:  2010-05       Impact factor: 4.618

3.  Genetic targeting aromatase in male amyloid precursor protein transgenic mice down-regulates beta-secretase (BACE1) and prevents Alzheimer-like pathology and cognitive impairment.

Authors:  Carrie McAllister; Jiangang Long; Adrienne Bowers; Aaron Walker; Philip Cao; Shin-Ichiro Honda; Nobuhiro Harada; Matthias Staufenbiel; Yong Shen; Rena Li
Journal:  J Neurosci       Date:  2010-05-26       Impact factor: 6.167

4.  Chronic peripheral administration of somatostatin receptor subtype-4 agonist NNC 26-9100 enhances learning and memory in SAMP8 mice.

Authors:  Karin E Sandoval; Susan A Farr; William A Banks; Michael L Niehoff; John E Morley; Albert M Crider; Ken A Witt
Journal:  Eur J Pharmacol       Date:  2010-12-24       Impact factor: 4.432

Review 5.  Disease-modifying therapies in Alzheimer's disease: how far have we come?

Authors:  Michael Hüll; Mathias Berger; Michael Heneka
Journal:  Drugs       Date:  2006       Impact factor: 9.546

6.  Altered NEP2 expression and activity in mild cognitive impairment and Alzheimer's disease.

Authors:  Jeffrey Y Huang; Daniel M Hafez; Bryan D James; David A Bennett; Robert A Marr
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

7.  Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing.

Authors:  Yi Wen; W Haung Yu; Bryan Maloney; Jason Bailey; Junrong Ma; Isabelle Marié; Thomas Maurin; Lili Wang; Helen Figueroa; Mathieu Herman; Pavan Krishnamurthy; Li Liu; Emmanuel Planel; Lit-Fui Lau; Debomoy K Lahiri; Karen Duff
Journal:  Neuron       Date:  2008-03-13       Impact factor: 17.173

8.  Neuropeptide Y fragments derived from neprilysin processing are neuroprotective in a transgenic model of Alzheimer's disease.

Authors:  John B Rose; Leslie Crews; Edward Rockenstein; Anthony Adame; Michael Mante; Louis B Hersh; Fred H Gage; Brian Spencer; Rewati Potkar; Robert A Marr; Eliezer Masliah
Journal:  J Neurosci       Date:  2009-01-28       Impact factor: 6.167

Review 9.  Transgenic Drosophila models of Alzheimer's disease and tauopathies.

Authors:  Kanae Iijima-Ando; Koichi Iijima
Journal:  Brain Struct Funct       Date:  2009-12-05       Impact factor: 3.270

10.  Drosophila Neprilysins Are Involved in Middle-Term and Long-Term Memory.

Authors:  Oriane Turrel; Aurélie Lampin-Saint-Amaux; Thomas Préat; Valérie Goguel
Journal:  J Neurosci       Date:  2016-09-14       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.